Literature DB >> 32058276

Pathogenic and protective roles of cytokines in pemphigus: A systematic review.

Soheil Tavakolpour1, HamidReza Mahmoudi2, Azin Mirzazadeh3, Kamran Balighi2, Sahar Darabi-Monadi4, SeyedehBehnaz Hatami4, Mojtaba GhasemiAdl5, Maryam Daneshpazhooh2.   

Abstract

Pemphigus is a rare and life-threatening group of blistering autoimmune diseases that affects the skin and mucous membranes. There are two major subtypes of pemphigus, including pemphigus vulgaris (PV) and pemphigus foliaceus (PF); each has different clinical manifestations. Pemphigus cannot be considered as a single disease and each patient may have a specific immunological profile. There are a lot of studies available regarding the role of different cytokines in the pathogenesis of pemphigus, although the data are not coherent between different studies. In this study, a systematic review from inception to December 25, 2019, through the MEDLINE/PubMed database had been performed to address several aspects of cytokines' roles in PV and PF. As a result, 57 studies from 352 initially found records, containing 26 cytokines had met the inclusion criteria. We found different pieces of evidence in favor of increased levels of TNF-α, TGF-β, interleukin (IL)-8, IL-10, IL-12, IL-17, IL-21; while decreased levels of IL-2 and IL-23 in pemphigus patients. Regarding other cytokines, such as IFN-γ, IL-5, IL-15, IL-22, there are controversial results. Different studies suggested the association of TNF-α and IL-6 with disease activity and autoantibodies values. However, there is uncertainty regarding the role of IFN-γ, IL-2, IL-15, IL-27, and IL-33. Treatments with immunosuppressive agents may decrease IL-1, IL-6, IL-8, IFN-γ, IL-33, IL-17 levels. In conclusion, cytokines are deeply involved in PV and PF pathogenesis, and targeting specific cytokines may lead to development of more promising treatments for pemphigus.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokine, Interleukin; Pemphigus; Treatment

Year:  2020        PMID: 32058276     DOI: 10.1016/j.cyto.2020.155026

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

Review 1.  The emerging role of T cells in pemphigus vulgaris: a systematic review.

Authors:  Farnaz Araghi; Sahar Dadkhahfar; Reza M Robati; Mohammadreza Tabary; Mohammad Shahidi-Dadras
Journal:  Clin Exp Med       Date:  2022-08-04       Impact factor: 5.057

2.  Clinical, Histopathologic, and Immunohistochemical Features of Patients with IgG/IgA Pemphigus.

Authors:  Yung-Tsu Cho; Ko-Ting Fu; Kai-Lung Chen; Yih-Leong Chang; Chia-Yu Chu
Journal:  Biomedicines       Date:  2022-05-22

3.  Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls.

Authors:  Pegah Shahbazian; Maryam Izad; Maryam Daneshpazhooh; Hossein Mortazavi; Zahra Salehi; Shirin Behruzifar; Soheil Tavakolpour; Arghavan Azizpour
Journal:  Dermatol Pract Concept       Date:  2021-04-12

4.  Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.

Authors:  Fateme Shirzad Moghadam; Nika Kianfar; Shayan Dasdar; Rana Samii; Zeinab Farimani; Pedram Molhem Azar; Kamran Balighi; Robabeh Abedini; Tahereh Soori; Ali Salehi Farid; Hamidreza Mahmoudi; Maryam Daneshpazhooh
Journal:  Dermatol Ther       Date:  2022-07-21       Impact factor: 3.858

5.  Innate immune activation as cofactor in pemphigus disease manifestation.

Authors:  Ramona A Eichkorn; Morna F Schmidt; Elias Walter; Michael Hertl; Jens Malte Baron; Jens Waschke; Amir S Yazdi
Journal:  Front Immunol       Date:  2022-07-19       Impact factor: 8.786

Review 6.  Marked to Die-Cell Death Mechanisms for Keratinocyte Acantholysis in Pemphigus Diseases.

Authors:  Valéria Bumiller-Bini Hoch; Larissa Schneider; Anna Elisabeth Pumpe; Emelie Lüders; Jennifer Elisabeth Hundt; Angelica Beate Winter Boldt
Journal:  Life (Basel)       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.